A carregar...
Second-Generation ALK Inhibitors: Filling the Non “MET” Gap
Ceritinib and other second-generation inhibitors have demonstrated promising anticancer activity in anaplastic lymphoma kinase (ALK)–positive non–small cell lung cancer (NSCLC). Specifically, they can overcome resistance due to certain gatekeeper mutations acquired following crizotinib exposure. The...
Na minha lista:
| Publicado no: | Cancer Discov |
|---|---|
| Main Authors: | , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
2014
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4551422/ https://ncbi.nlm.nih.gov/pubmed/24891360 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/2159-8290.CD-14-0410 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|